Cargando…

Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes

Rift Valley fever virus (RVFV) is a mosquito‐borne pathogen with significant human and veterinary health consequences that periodically emerges in epizootics. RVFV causes fetal loss and death in ruminants and in humans can lead to liver and renal disease, delayed‐onset encephalitis, retinitis, and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Corey L., Snell, Trey K., Bennett, Susi, Wyckoff, John H., Heaslip, Darragh, Flatt, Jordan, Harris, Emma K., Hartman, Daniel A., Lian, Elena, Bird, Brian H., Stenglein, Mark D., Bowen, Richard A., Kading, Rebekah C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788258/
https://www.ncbi.nlm.nih.gov/pubmed/34890118
http://dx.doi.org/10.1111/tbed.14415
_version_ 1784858710617620480
author Campbell, Corey L.
Snell, Trey K.
Bennett, Susi
Wyckoff, John H.
Heaslip, Darragh
Flatt, Jordan
Harris, Emma K.
Hartman, Daniel A.
Lian, Elena
Bird, Brian H.
Stenglein, Mark D.
Bowen, Richard A.
Kading, Rebekah C.
author_facet Campbell, Corey L.
Snell, Trey K.
Bennett, Susi
Wyckoff, John H.
Heaslip, Darragh
Flatt, Jordan
Harris, Emma K.
Hartman, Daniel A.
Lian, Elena
Bird, Brian H.
Stenglein, Mark D.
Bowen, Richard A.
Kading, Rebekah C.
author_sort Campbell, Corey L.
collection PubMed
description Rift Valley fever virus (RVFV) is a mosquito‐borne pathogen with significant human and veterinary health consequences that periodically emerges in epizootics. RVFV causes fetal loss and death in ruminants and in humans can lead to liver and renal disease, delayed‐onset encephalitis, retinitis, and in some cases severe haemorrhagic fever. A live attenuated vaccine candidate (DDVax), was developed by the deletion of the virulence factors NSs and NSm from a clinical isolate, ZH501, and has proven safe and immunogenic in rodents, pregnant sheep and non‐human primates. Deletion of NSm also severely restricted mosquito midgut infection and inhibited vector‐borne transmission. To demonstrate environmental safety, this study investigated the replication, dissemination and transmission efficiency of DDVax in mosquitoes following oral exposure compared to RVFV strains MP‐12 and ZH501. Infection and dissemination profiles were also measured in mosquitoes 7 days after they fed on goats inoculated with DDvax or MP‐12. We hypothesized that DDVax would infect mosquitoes at significantly lower rates than other RVFV strains and, due to lack of NSm, be transmission incompetent. Exposure of Ae. aegypti and Cx. tarsalis to 8 log(10) plaque forming units (PFU)/ml DDVax by artificial bloodmeal resulted in significantly reduced DDVax infection rates in mosquito bodies compared to controls. Plaque assays indicated negligible transmission of infectious DDVax in Cx. tarsalis saliva (1/140 sampled) and none in Ae. aegypti saliva (0/120). Serum from goats inoculated with DDVax or MP‐12 did not harbour detectable infectious virus by plaque assay at 1, 2 or 3 days post‐inoculation. Infectious virus was, however, recovered from Aedes and Culex bodies that fed on goats vaccinated with MP‐12 (13.8% and 4.6%, respectively), but strikingly, DDvax‐positive mosquito bodies were greatly reduced (4%, and 0%, respectively). Furthermore, DDVax did not disseminate to legs/wings in any of the goat‐fed mosquitoes. Collectively, these results are consistent with a beneficial environmental safety profile.
format Online
Article
Text
id pubmed-9788258
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97882582022-12-28 Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes Campbell, Corey L. Snell, Trey K. Bennett, Susi Wyckoff, John H. Heaslip, Darragh Flatt, Jordan Harris, Emma K. Hartman, Daniel A. Lian, Elena Bird, Brian H. Stenglein, Mark D. Bowen, Richard A. Kading, Rebekah C. Transbound Emerg Dis Original Articles Rift Valley fever virus (RVFV) is a mosquito‐borne pathogen with significant human and veterinary health consequences that periodically emerges in epizootics. RVFV causes fetal loss and death in ruminants and in humans can lead to liver and renal disease, delayed‐onset encephalitis, retinitis, and in some cases severe haemorrhagic fever. A live attenuated vaccine candidate (DDVax), was developed by the deletion of the virulence factors NSs and NSm from a clinical isolate, ZH501, and has proven safe and immunogenic in rodents, pregnant sheep and non‐human primates. Deletion of NSm also severely restricted mosquito midgut infection and inhibited vector‐borne transmission. To demonstrate environmental safety, this study investigated the replication, dissemination and transmission efficiency of DDVax in mosquitoes following oral exposure compared to RVFV strains MP‐12 and ZH501. Infection and dissemination profiles were also measured in mosquitoes 7 days after they fed on goats inoculated with DDvax or MP‐12. We hypothesized that DDVax would infect mosquitoes at significantly lower rates than other RVFV strains and, due to lack of NSm, be transmission incompetent. Exposure of Ae. aegypti and Cx. tarsalis to 8 log(10) plaque forming units (PFU)/ml DDVax by artificial bloodmeal resulted in significantly reduced DDVax infection rates in mosquito bodies compared to controls. Plaque assays indicated negligible transmission of infectious DDVax in Cx. tarsalis saliva (1/140 sampled) and none in Ae. aegypti saliva (0/120). Serum from goats inoculated with DDVax or MP‐12 did not harbour detectable infectious virus by plaque assay at 1, 2 or 3 days post‐inoculation. Infectious virus was, however, recovered from Aedes and Culex bodies that fed on goats vaccinated with MP‐12 (13.8% and 4.6%, respectively), but strikingly, DDvax‐positive mosquito bodies were greatly reduced (4%, and 0%, respectively). Furthermore, DDVax did not disseminate to legs/wings in any of the goat‐fed mosquitoes. Collectively, these results are consistent with a beneficial environmental safety profile. John Wiley and Sons Inc. 2022-01-05 2022-09 /pmc/articles/PMC9788258/ /pubmed/34890118 http://dx.doi.org/10.1111/tbed.14415 Text en © 2021 The Authors. Transboundary and Emerging Diseases published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Campbell, Corey L.
Snell, Trey K.
Bennett, Susi
Wyckoff, John H.
Heaslip, Darragh
Flatt, Jordan
Harris, Emma K.
Hartman, Daniel A.
Lian, Elena
Bird, Brian H.
Stenglein, Mark D.
Bowen, Richard A.
Kading, Rebekah C.
Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes
title Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes
title_full Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes
title_fullStr Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes
title_full_unstemmed Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes
title_short Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes
title_sort safety study of rift valley fever human vaccine candidate (ddvax) in mosquitoes
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788258/
https://www.ncbi.nlm.nih.gov/pubmed/34890118
http://dx.doi.org/10.1111/tbed.14415
work_keys_str_mv AT campbellcoreyl safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes
AT snelltreyk safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes
AT bennettsusi safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes
AT wyckoffjohnh safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes
AT heaslipdarragh safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes
AT flattjordan safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes
AT harrisemmak safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes
AT hartmandaniela safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes
AT lianelena safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes
AT birdbrianh safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes
AT stengleinmarkd safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes
AT bowenricharda safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes
AT kadingrebekahc safetystudyofriftvalleyfeverhumanvaccinecandidateddvaxinmosquitoes